{"id":476732,"date":"2021-04-15T08:02:06","date_gmt":"2021-04-15T12:02:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-announces-publication-in-nature-reviews-neurology-highlighting-the-role-of-non-invasive-vagus-nerve-stimulation-nvns-as-an-emerging-treatment-for-cluster-headache\/"},"modified":"2021-04-15T08:02:06","modified_gmt":"2021-04-15T12:02:06","slug":"electrocore-announces-publication-in-nature-reviews-neurology-highlighting-the-role-of-non-invasive-vagus-nerve-stimulation-nvns-as-an-emerging-treatment-for-cluster-headache","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-announces-publication-in-nature-reviews-neurology-highlighting-the-role-of-non-invasive-vagus-nerve-stimulation-nvns-as-an-emerging-treatment-for-cluster-headache\/","title":{"rendered":"electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache"},"content":{"rendered":"
\n

\n \n <\/p>\n

ROCKAWAY, NJ, April 15, 2021 (GLOBE NEWSWIRE) — electroCore, Inc.\u00a0(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, \u201cCluster headache pathophysiology \u2014 insights from current and emerging treatments,\u201d\u00a0by Drs. Diana Wei and Peter Goadsby in Nature Reviews: Neurology.1<\/sup><\/em><\/p>\n

The paper reviews data on existing and emerging treatments for the acute and preventive treatment of cluster headache, as well as insights into the pathophysiology of cluster headache. Cluster headache is a debilitating primary headache disorder that affects approximately 0.1% of populations studied, a prevalence similar to that of multiple sclerosis.<\/p>\n

Among the emerging treatments, electrocore\u2019s gammaCore is identified as the only therapy that has been shown to be effective in clinical trials for both the acute treatment of episodic cluster headache as well as the preventive treatment of cluster headache. This dual ability offers a unique, nonpharmaceutical advantage to patients suffering from cluster headache who are looking for a treatment that can both acutely decrease or eliminate the pain from an acute cluster headache in as soon as 15 minutes, as well as decrease the number of weekly attacks they experience.<\/p>\n

\u201cGreat strides have been made in the treatment of cluster headache in the past decade,\u201d commented Dr.\u00a0Peter Goadsby, Professor of Neurology at UCLA, and co-author of the study. \u201cTreatment options such as nVNS may benefit individuals with cluster headache and have a substantial economic impact both directly by decreasing the overall cost of healthcare and indirectly by reducing absence from work and reduced work efficiency due to cluster headaches.\u201d<\/p>\n

\u201cWe compliment the authors on their rigorous review of current and emerging treatment options and on the publication, which highlights progress in the study of cluster headache and the evolution of its treatment. nVNS, which is unique in its ability to be used acutely or preventively by patients suffering from cluster headache, is ideally suited to help these patients manage their devastating attacks while decreasing the overall costs to healthcare systems,\u201d said Eric Liebler, Senior Vice President of Neurology of electroCore.<\/p>\n

For more information, visit https:\/\/www.nature.com\/nrneurol\/.<\/p>\n

\n About electroCore, Inc.<\/strong>\n <\/p>\n

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.<\/p>\n

For more information, visit www.electrocore.com.<\/p>\n

\n About gammaCoreTM<\/sup><\/strong>\n <\/p>\n

gammaCoreTM<\/sup> (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient\u2019s neck over the vagus nerve, gammaCore stimulates the nerve\u2019s afferent fibers, which may lead to a reduction of pain in patients.<\/p>\n

gammaCore (nVNS) is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and\/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.<\/p>\n

gammaCore contraindications include but are not limited to:<\/p>\n